This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
OLIG2 / Oligodendrocyte transcription factor 2 · IHC design guide
Design Immunohistochemistry for OLIG2
Plan OLIG2 chromogenic IHC in paraffin sections around nuclear staining in subsets of glial cells (HPA tissue IHC). Use cerebral cortex glial cells as a positive control (HPA tissue IHC) and score nuclear signal while accounting for variable expression in glioblastomas (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
OLIG2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Selective nuclear staining in glial cells (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in subsets of glial cells (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Glioblastoma expression is highly variable (UniProt) | |
| Regulation | Strong in oligodendrogliomas (UniProt) | |
| Isoform / epitope | No annotated isoforms; one 1–323 chain (UniProt) |
Section 1
Recommended OLIG2 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is followed by published OLIG2 chromogenic IHC methods for tissue sections, brain tumors, and lung specimens (PMC13013231; PMC3161192; PMC10060425).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A02247-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-OLIG2, 5 μg/mL (datasheet A02247-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | OLIG2-positive staining in granular cells - nucleus of cerebellum (HPA tissue IHC: High). HPA tissue profile: Selective nuclear expression in subsets of glial cells. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 HIER at 95–98 °C for 20 min (page retrieval; UniProt: nucleus). Optimize for the antibody used.
Section 2
What Is the Expected OLIG2 Staining Pattern?
In paraffin-section IHC, expect OLIG2 in selected nuclei, especially glial cells in brain tissue (HPA: Enhanced tissue IHC; selective nuclear expression in glial subsets). Cerebellar granular-cell nuclei are also reported positive (HPA: High). OLIG2 is a non-membrane protein annotated in both nucleus and cytoplasm (UniProt Q13516: topology and subcellular location), so interpret compartment alongside the observed tissue pattern.
| Distinct nuclear staining in a subset of cerebral-cortex, caudate, or hippocampal glial cells. | This matches the reported selective pattern; staining need not fill every cell in the field (HPA: selective nuclear expression in glial subsets; Medium in these tissues). Score the proportion and intensity of positive nuclei separately so a sparse positive population is distinguishable from diffuse background (general IHC practice). |
| Strong nuclear staining in cerebellar granular cells. | This is an expected positive appearance for this sampled cell population (HPA: cerebellum, granular-cell nuclei, High). Compare signal with neighboring unstained structures on the same section; a brown deposit across nuclei and surrounding tissue is less persuasive than nuclei with clear boundaries (general IHC practice). |
| Predominantly diffuse cytoplasmic or membrane staining, with little selective nuclear signal. | Review this as a compartment mismatch against the tissue-IHC pattern (HPA: selective nuclear expression). Cytoplasmic OLIG2 remains biologically plausible (UniProt Q13516: nucleus and cytoplasm); membrane localization is uncertain in ICC-IF (HPA: subcellular). Neither observation alone establishes a specific positive IHC result. |
| Staining appears in cell populations reported as undetected, such as adipocytes in adipose tissue. | Treat this as unexpected for that specimen and cell type (HPA: adipose-tissue adipocytes, Not detected). Examine cross-reactivity, nonspecific binding, and endogenous detection activity with appropriate controls (general IHC practice). Do not apply a blanket negative rule to every non-glial cell: placental cytotrophoblasts are reported Medium (HPA: tissue IHC). |
| No nuclear signal in a section expected to contain positive cells. | A blank result in cerebellar granular cells or the listed brain glial populations conflicts with their observed staining (HPA: High in cerebellar granular-cell nuclei; Medium in listed glia). Check the sampled cell population and run a known-positive section through the same staining run before interpreting the experimental section as OLIG2 negative (general IHC practice). |
💡Expected OLIG2 appearanceCall a result positive when selected glial nuclei show clear, moderate staining, or cerebellar granular-cell nuclei show strong staining (HPA: Medium in listed glia; High in cerebellum); widespread diffuse deposit or staining without a matching nuclear population is suspect (general IHC practice).
| Cell population and tissue | Brain RNA is tissue enriched, while tissue IHC identifies specific positive cells rather than uniform tissue-wide staining (HPA: RNA tissue enriched in Brain; selective nuclear expression). Placental cytotrophoblasts are a documented additional positive population (HPA: Medium), so identify cells before scoring an unusual tissue result. |
| Compartment | The tissue-IHC reference pattern is nuclear (HPA: selective nuclear expression). UniProt also annotates cytoplasm and notes that the bHLH-domain nuclear-localization signal may be masked in native OLIG2 (UniProt Q13516: subcellular note). This supports cautious interpretation of cytoplasmic signal, without predicting its frequency in paraffin sections. |
| Molecular features | OLIG2 has no transmembrane segment, signal peptide, propeptide, or annotated glycosylation sites; the reported chain spans residues 1–323 (UniProt Q13516: topology, processing, glycosylation). These records give no target-specific basis to predict a fixation or retrieval effect. |
| Antibody evidence | Two listed antibodies have Enhanced IHC status (HPA: HPA003254 and CAB019381). That supports the reported tissue pattern; it does not establish that an unlisted catalog antibody will reproduce it. Validate the chosen antibody against a known-positive population and an appropriate negative control (general IHC practice). |
| IF/ICC Q: Should membrane signal count as expected OLIG2 staining? | A: Nucleoplasm is the main ICC-IF location, while the additional plasma-membrane location is marked uncertain (HPA: subcellular ICC-IF). For this paraffin IHC interpretation, prioritize the selective nuclear tissue pattern (HPA: tissue IHC); assess IF/ICC staining with its separate guide. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive cerebellar granular-cell nuclei have no signal. | The result disagrees with the reported High nuclear staining (HPA: cerebellum); specimen sampling or an unsuccessful staining run are possible explanations (general IHC practice). | Confirm that granular cells are present, then compare a known-positive section stained in the same run. Review antibody preparation, retrieval conditions, and detection reagents using the assay's documented procedure (general IHC practice). |
| Brain section has weak, hard-to-score nuclear staining. | Some listed glial populations are reported at Medium intensity and occur as subsets (HPA: caudate, cortex, hippocampus; selective glial nuclei). Weak contrast can also complicate visual scoring (general IHC practice). | Identify the expected cell population, inspect a positive control from the same run, and score nuclear signal against local background. Check the assay's documented antibody and detection conditions before changing them (general IHC practice). |
| Diffuse brown deposit obscures nuclei throughout the section. | Broad deposit does not resemble selective nuclear expression (HPA: tissue IHC). Nonspecific antibody binding or endogenous detection activity may contribute to chromogenic background (general IHC practice). | Compare with a no-primary control, review blocking and wash steps, and check the chromogenic detection controls. Reassess whether discrete positive nuclei become visible after background is controlled (general IHC practice). |
| Strong cytoplasmic staining dominates, with few identifiable positive nuclei. | The balance conflicts with the tissue-IHC reference pattern (HPA: selective nuclear expression), although cytoplasm is an annotated OLIG2 location (UniProt Q13516: subcellular location). | Check nuclear counterstain and cell boundaries, then compare a known-positive tissue and a no-primary control from the same run. Record cytoplasmic signal separately; avoid calling it a confirmed positive nuclear pattern (general IHC practice). |
| Cells expected to be negative show convincing chromogen. | For example, adipose-tissue adipocytes are reported Not detected (HPA: tissue IHC). Cross-reactivity, nonspecific binding, or endogenous detection activity are possible assay explanations (general IHC practice). | Verify the tissue and cell identity, examine a no-primary control, and compare the chosen antibody with its validation information. Use the reported cell-specific pattern when judging the result (HPA: tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing OLIG2 staining
A02247-1 · IHCImmunohistochemistry of OLIG2 in rat brain tissue with OLIG2 antibody at 5 μg/mL.
A02247-1 · IHCImmunohistochemistry of OLIG2 in mouse brain tissue with OLIG2 Antibody at 5 μg/mL.
A02247-1 · IFImmunofluorescence of OLIG2 in rat brain tissue with OLIG2 antibody at 20 μg/mL.
M02247 · IHCImmunohistochemical analysis of paraffin-embedded human mouse brain, using Olig2 Antibody.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000205927-OLIG2/tissue/cerebral+cortex#imid_4949248
HPA · CaudateHuman Protein Atlas IHC, Caudate. Source: https://www.proteinatlas.org/ENSG00000205927-OLIG2/tissue/basal+ganglia#imid_4949234
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000205927-OLIG2/tissue/colon#imid_4949158
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000205927-OLIG2/tissue/liver#imid_4949167
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA003254; green = OLIG2, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA003254; green = OLIG2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for OLIG2 IHC & IF
🧪Run cerebellum first and look for nuclear staining in granular cells (HPA: High in cerebellar granular-cell nuclei). Use adipose tissue as a negative comparator (HPA: adipocytes Not detected); cells on the cerebellar slide without nuclear signal provide internal negative comparators.
Positive control tissue: Cerebellum (Granular cells - nucleus, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show OLIG2 in A-431, U-251MG, U2OS, with annotated localisation: Nucleoplasm (uncertain) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-matched, clonality-matched isotype controls, plus OLIG2-knockout tissue if available (standard IHC practice). In cerebellum, block endogenous peroxidase and check that the no-primary slide has no chromogenic signal (standard chromogenic IHC practice).
⚠️Feasibility: The supplied evidence reports no OLIG2-specific fixation window or retrieval dependency, so determine retrieval conditions empirically; the selected A02247-1 rat-brain IHC caption does not report a fixative (selected SKU caption: fixative not stated). Whether frozen sections or IF are easier is unreported. Interpret nuclear staining against local background because the expected positive compartment is the nucleus (HPA: High in cerebellar granular-cell nuclei; UniProt Q13516: nucleus).
HPA tissue IHC evidence for OLIG2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Granular cells - nucleus | High | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | Medium | Protein (IHC) | HPA → |
| Hippocampus | Glial cells | Medium | Protein (IHC) | HPA → |
| Placenta | Cytotrophoblasts | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced OLIG2 IHC Tips
Troubleshoot OLIG2 staining in paraffin-section chromogenic IHC, with an IF note for confirming cell identity and nuclear localisation.
How should I adjust retrieval when OLIG2 nuclear staining is weak?
Start with Tris-EDTA pH 9.0 heat-induced retrieval at 95–98 °C for 20 min (page retrieval rule: nuclear antigen). If nuclei remain faint, check that sections reached the intended temperature and cooled consistently before changing chemistry (standard IHC practice). Compare a small retrieval time series on adjacent sections while holding antibody concentration and detection conditions constant (standard IHC practice). A rat brain IHC image used the catalog antibody at 5 µg/mL, but its caption reports no retrieval method (selected A02247-1 tissue-IHC caption). Score nuclear signal alongside tissue integrity, because excessive heating can damage morphology and obscure cell identification (standard IHC practice).
Could fixation explain variable OLIG2 staining between paraffin blocks?
OLIG2-specific fixation sensitivity is unknown from the supplied evidence; the rat brain IHC caption does not state its fixative (selected A02247-1 tissue-IHC caption). Record fixative, fixation duration, processing history and section age for each block before comparing staining (standard IHC practice). When feasible, stain adjacent sections from differently processed blocks in one run with the same retrieval and detection conditions (standard IHC practice). Compare nuclear signal and morphology in the same anatomical region, since processing differences can affect antigen accessibility in paraffin sections (standard IHC practice). Do not assign a particular fixation effect to OLIG2 without a direct comparison (supplied evidence: no target-specific fixation study).
Should diffuse cytoplasmic OLIG2 staining count as positive?
Use nuclear staining as the principal chromogenic readout: tissue IHC shows selective nuclear expression in subsets of glial cells (HPA tissue IHC). UniProt also lists cytoplasm and notes that nuclear entry may involve partner interactions, so cytoplasmic signal merits review rather than automatic dismissal (UniProt Q13516 localisation note). Compare stained cells with adjacent nuclear counterstain, and document nuclear and cytoplasmic compartments separately (standard IHC practice). If diffuse cytoplasmic color dominates many cell types, check primary-omission controls, detection background and section edges before scoring (standard IHC practice). HPA's plasma-membrane assignment is uncertain and derives from subcellular IF data (HPA subcellular).
How can I assess whether retrieval has hidden the OLIG2 epitope?
The supplied record lists 0 isoforms and places the bHLH domain at residues 108–162 (UniProt Q13516). It does not provide the catalog antibody's epitope, so a loss of staining cannot be assigned to that domain (supplied record; selected A02247-1 tissue-IHC caption). Compare adjacent sections across the page's Tris-EDTA pH 9.0 retrieval condition and a restrained time series while keeping antibody and detection steps fixed (page retrieval rule; standard IHC practice). Include a known staining region on each run to distinguish a section-wide failure from regional expression differences (HPA tissue IHC; standard IHC practice). Avoid interpreting altered signal as isoform selection without epitope evidence (UniProt Q13516 isoform record).
How could IF help resolve ambiguous OLIG2 staining in tissue?
Use IF on a comparable section to assess OLIG2 overlap with a marker for the expected glial cell population and with a nuclear counterstain (HPA tissue IHC; standard IF practice). Choose fluorophores after inspecting unstained tissue autofluorescence, and reserve a spectrally distinct channel for the cell marker (standard IF practice). OLIG2 is recorded in the nucleus and cytoplasm, but the catalog antibody's epitope is unspecified (UniProt Q13516; supplied catalog evidence). Apply and titrate permeabilisation if detecting an intracellular epitope, then compare with a minimally permeabilised condition to check background (standard IF practice). Treat the rat brain 5 µg/mL chromogenic image as IHC evidence, not IF validation (selected A02247-1 tissue-IHC caption).
What should I check when OLIG2 DAB staining spreads beyond nuclei?
Compare primary-omission and detection-only controls with the stained section to locate nonspecific signal from the detection workflow (standard IHC practice). For chromogenic IHC, verify the peroxidase block and inspect endogenous pigment before attributing brown deposits to OLIG2 (standard IHC practice). Review blocking, washing and antibody concentration together; the selected rat brain image used 5 µg/mL, which is an image condition rather than a demonstrated optimum for every specimen (selected A02247-1 tissue-IHC caption). Focus interpretation on discrete nuclei in the relevant cell population, since HPA reports selective nuclear expression in subsets of glial cells (HPA tissue IHC). Record edge staining separately from interpretable interior fields (standard IHC practice).
How should I quantify OLIG2 positivity across heterogeneous sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the anatomical region and eligible cell population before counting, because OLIG2 staining is selective among glial cells and varies by tissue context (HPA tissue IHC). Report the percentage of positive nuclei among all eligible nuclei, using a consistent intensity threshold and nuclear counterstain (standard IHC practice). If intensity matters, add a nuclear H-score; if cellular abundance matters, report positive nuclei per mm² of viable tissue (standard IHC practice). Normalise counts to the eligible nuclear population or measured viable area, and exclude folds, edges and necrotic regions using predefined rules (standard IHC practice). Keep cytoplasmic staining as a separate observation from the nuclear score (UniProt Q13516 localisation; standard IHC practice).
When is an OLIG2-positive pattern convincing rather than artefactual?
A convincing result shows discrete nuclear staining in an appropriate cell population, consistent with selective nuclear staining in subsets of glial cells (HPA tissue IHC). Interpret tissue context carefully: UniProt reports brain oligodendrocyte expression and variable expression across glioma types, while HPA also reports nuclear staining in cerebellar granular cells (UniProt Q13516 tissue specificity; HPA tissue IHC). Diffuse color in unrelated cells, a strong section-edge gradient or staining confined to necrosis warrants review of controls and morphology (standard IHC practice). Exclude pigment and endogenous peroxidase effects with appropriate detection controls before calling weak brown deposits positive (standard IHC practice). Document any cytoplasmic staining separately because UniProt also lists cytoplasmic localisation (UniProt Q13516).
Boster reagents
Best OLIG2 / Oligodendrocyte transcription factor 2 IHC Antibodies
Catalog anti-OLIG2 antibodies have IHC images of rat and mouse brain and IF images of rat and mouse brain (A02247-1 image captions); both list human, mouse and rat reactivity (catalog reactivity).
Real IHC data
Anti-OLIG2 Antibody
Cat # A02247-1
Real IHC data
Anti-Olig2 Rabbit Monoclonal Antibody
Cat # M02247
A02247-1 has rat and mouse brain IHC and IF images, with IHC-P and IF listed as applications (A02247-1 image captions; catalog applications). M02247 lists IHC and ICC/IF, but its only supplied image caption describes paraffin-embedded “human mouse brain” IHC; no IF image is supplied (M02247 catalog applications; IHC and IF image captions).
Which to pick: For tissue IHC, choose A02247-1 for rat or mouse brain evidence, or M02247 when a paraffin-section example is useful; the M02247 caption does not report the fixative (A02247-1 IHC captions; M02247 IHC caption). For tissue IF, A02247-1 has rat and mouse brain images; for ICC, M02247 lists the application but supplies no ICC image (A02247-1 IF captions; M02247 catalog applications and image captions). For work across human, mouse and rat, both list reactivity with all three species, while M02247 is a rabbit monoclonal and A02247-1 has no clone specified (catalog reactivity; catalog host and clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q13516 (OLIG2_HUMAN, Oligodendrocyte transcription factor 2).
- Human Protein Atlas. OLIG2 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. OLIG2 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the plasma membrane..
- Human Protein Atlas. OLIG2 antibody validation summary (2 antibodies).
- OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Diagnostic pathology 2019 — PMC6731563.
- Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes. Acta neuropathologica 2026 — PMC13013231.
- OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. Journal of neuro-oncology 2011 — PMC3161192.
- ACT001 inhibited CD133 transcription by targeting and inducing Olig2 ubiquitination degradation. Oncogenesis 2023 — PMC10060425.
- PubMed PMID:10737801 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for OLIG2 (Oligodendrocyte transcription factor 2). Expected localisation Selective nuclear staining in glial cells (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A02247-1 at 5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Granular cells - nucleus); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A02247-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-OLIG2, 5 μg/mL (datasheet A02247-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Glioblastoma expression is highly variable (UniProt); Isoform / epitope: No annotated isoforms; one 1–323 chain (UniProt); Regulation: Strong in oligodendrogliomas (UniProt). Evidence: UniProt Q13516, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A02247-1, PMC13013231, PMC3161192. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/OLIG2/immunohistochemistry-ihc-guide.